ReviewDiscover oncology2025
Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advancements in cancer treatment, including targeted therapy, tailored vaccines, immunotherapy, and bacteriotherapy, have demonstrated remarkable potential in addressing various types of cancer. However, the pursuit of novel therapeutic strategies remains challenged by significant obstacles, including toxicity to healthy tissues, limited penetration into malignant tissues, and the potential for tumor cell resistance to pharmacological agents. This study explored the potential of tailored vaccinations, immunotherapy, CRISPR/Cas9, and bacteriotherapy for cancer treatment. Randomized and non-randomized studies were reviewed using the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed (NCBI), Scopus (ELSEVIER), and Web of Science (CLAVIRATE) databases. This research highlights the promising use of personalized cancer vaccines, which induce tumor-specific immune responses targeting neoantigens unique to each patient. Immunotherapy, which enhances the ability of the immune system to identify and destroy cancer cells, has revitalized tumor immunology. While the effectiveness of immunotherapies, such as immune checkpoint inhibitors (ICIs) and adoptive cell transfer (ACT), is variable, certain cancer patients show substantial benefits. Bacteriotherapy has also proven effective in promoting tumor remission and inhibiting metastasis, either alone or in combination with conventional treatments, by reducing tumor proliferation and metastasis. Additionally, bacteriotherapy serves as a potential platform for delivering therapeutics, genes, or medications directly to tumors. The CRISPR-Cas9 genome-editing technique shows promise for advancing cancer treatment, with the potential to target and treat genetic mutations at the tumor level, although its application in human cancer therapy is still under development. This study highlights the potential of these innovative approaches in the fight against cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.